{"id":235857,"date":"2020-07-31T16:41:19","date_gmt":"2020-07-31T14:41:19","guid":{"rendered":"http:\/\/innovationorigins.com\/?p=235857"},"modified":"2020-07-31T16:41:19","modified_gmt":"2020-07-31T14:41:19","slug":"intravacc-goes-ahead-with-production-of-protein-based-covid-19-vaccine","status":"publish","type":"post","link":"https:\/\/ioplus.nl\/archive\/en\/intravacc-goes-ahead-with-production-of-protein-based-covid-19-vaccine\/","title":{"rendered":"Intravacc goes ahead with production of protein-based Covid-19 vaccine"},"content":{"rendered":"\n<p><a aria-label=\"undefined (opens in a new tab)\" href=\"https:\/\/www.intravacc.nl\/\" target=\"_blank\" rel=\"noreferrer noopener\">Intravacc<\/a> and <a aria-label=\"undefined (opens in a new tab)\" href=\"https:\/\/www.celonic.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Celonic Group<\/a> will further design, develop, and produce a Covid-19 vaccine based on an immunogenic Spike (S) protein of SARS-CoV-2. The product is combined with Intravacc\u2019s proprietary\u00a0<a href=\"https:\/\/www.intravacc.nl\/media\/1296\/intravacc-factsheet-omvs.pdf\">Outer Membrane Vesicle (OMV) technology<\/a>. <\/p>\n\n\n\n<p>Intravacc is a global leader in translational research and the development of viral and bacterial vaccines. Celonic Group is, a premium biopharmaceutical contract development and manufacturing organization (CDMO), specialized in the development and production of Advanced Therapy Medicinal Products (ATMP) and mammalian cell lines expressed bio-therapeutics. <\/p>\n\n\n\n<p>In the beginning of March this year Intravacc started working on the development of four candidate coronavirus vaccines based on three proprietary technologies: Vero cell, OMV, and iBoost.<\/p>\n\n\n\n<p><strong><em><a href=\"https:\/\/innovationorigins.com\/?s=intravacc\" target=\"_blank\" aria-label=\"undefined (opens in a new tab)\" rel=\"noreferrer noopener\">Read more on Intravacc&#8217;s research here<\/a><\/em><\/strong><\/p>\n\n\n\n<p>For this specific joint vaccine development, Intravacc combines its immunogenic OMV delivery platform with S-proteins expressed by Celonic Group\u2019s CHOvolution\u00a0mammalian cell expression system. This should result in generating an effective and balanced B and T cell response against SARS-CoV-2. Swiss-based Celonic Group will construct cell lines producing the\u00a0 S-protein in high quantities and develop a GMP production process.<\/p>\n\n\n\n<p>Preclinical studies will start shortly to select the best candidate protein for the vaccine. The collaboration aims to accelerate the development of Intravacc\u2019s COVID-19 OMV protein vaccine, which is expected to enter clinical testing in 2021.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/archive.ioplus.nl\/wp-content\/uploads\/2020\/03\/headshotjg2.jpg\" alt=\"\" class=\"wp-image-213954\"\/><figcaption>CEO Jan Groen, Intravacc<\/figcaption><\/figure>\n\n\n\n<p>Dr. Jan Groen, Intravacc\u2019s Chief Executive Officer of Intravcc claims that several studies have shown that\u00a0OMVs have the\u00a0ability to enhance the immune response and can be formulated with target-specific peptides and proteins. &#8220;This, combined with the fact they can be quickly scaled-up for manufacturing, makes it an ideally suited platform under the current circumstances where quantity and speed are critical.&#8221;<\/p>\n\n\n\n<p>Dr. Konstantin Matentzoglu, Chief Executive Officer of Celonic, adds that the novel vaccine has the potential to prevent morbidity and mortality of COVID-19. &#8220;Together, we have an opportunity to make a difference in the lives of patients at this time of great need.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Intravacc and Celonic Group will further design, develop, and produce a Covid-19 vaccine based on an immunogenic Spike (S) protein of SARS-CoV-2. The product is combined with Intravacc\u2019s proprietary\u00a0Outer Membrane Vesicle (OMV) technology. Intravacc is a global leader in translational research and the development of viral and bacterial vaccines. Celonic Group is, a premium biopharmaceutical [&hellip;]<\/p>\n","protected":false},"author":1594,"featured_media":517005,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[34665],"tags":[48127],"location":[6763],"article_type":[],"serie":[],"archives":[],"internal_archives":[],"reboot-archive":[],"class_list":["post-235857","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-covid-19","location-netherlands"],"blocksy_meta":[],"acf":{"subtitle":"\"Together, we have an opportunity to make a difference in the lives of patients at this time of great need.\"","text_display_homepage":false},"author_meta":{"display_name":"IO Eindhoven","author_link":"https:\/\/ioplus.nl\/archive\/author\/redactie-e52\/"},"featured_img":"https:\/\/ioplus.nl\/archive\/wp-content\/uploads\/2020\/03\/corona-4916954_1920-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/ioplus.nl\/archive\/en\/category\/health\/\" class=\"advgb-post-tax-term\">Health<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Health<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/ioplus.nl\/archive\/en\/category\/health\/\" class=\"advgb-post-tax-term\">COVID-19<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">COVID-19<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 6 years ago"},"absolute_dates":{"created":"Posted on July 31, 2020","modified":"Updated on July 31, 2020"},"absolute_dates_time":{"created":"Posted on July 31, 2020 4:41 pm","modified":"Updated on July 31, 2020 4:41 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/posts\/235857","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/users\/1594"}],"replies":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/comments?post=235857"}],"version-history":[{"count":0,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/posts\/235857\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/media\/517005"}],"wp:attachment":[{"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/media?parent=235857"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/categories?post=235857"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/tags?post=235857"},{"taxonomy":"location","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/location?post=235857"},{"taxonomy":"article_type","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/article_type?post=235857"},{"taxonomy":"serie","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/serie?post=235857"},{"taxonomy":"archives","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/archives?post=235857"},{"taxonomy":"internal_archives","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/internal_archives?post=235857"},{"taxonomy":"reboot-archive","embeddable":true,"href":"https:\/\/ioplus.nl\/archive\/wp-json\/wp\/v2\/reboot-archive?post=235857"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}